92.9 F
San Fernando
Saturday, Feb 24, 2024

Year In Review: Deals and Dealmakers of 2023

While 2023 may not have been the biggest year on record for deals involving Valley-area companies, there were still a number of noteworthy transactions, announcements and changes. In the biotech sector, the year started with the announcement that Woodland Hills-based late-stage clinical immunotherapy company Acelyrin Inc. would acquire ValenzaBio, an immunotherapy company based in Bethesda, Maryland. Thousand Oaks-based gene therapy company Capsida Biotherapeutics, meanwhile, signed a multiyear partnership deal with Prevail Therapeutics, a subsidiary of pharma giant Eli Lilly & Co. And in October Amgen Inc. closed on its $27.8 billion deal to acquire Horizon Therapeutics.

In the real estate sector, some big news included Hackman Capital Partners announcing a $1 billion modernization plan for Radford Studio Center in Studio City and Mountain View Manor, a 200-unit apartment building in Sylmar, selling for $39.5 million.

Perhaps the biggest news of the year, though, were the twin Hollywood strikes which saw both actors and screenwriters strike against the major Hollywood studios in separate actions that have both since been resolved.

This special report looks at a few of the biggest deals and dealmakers in the Valley area this year.


Hannah Madans Welk
Hannah Madans Welk
Hannah Madans Welk is Interim Editor at the Los Angeles Business Journal and the Inside The Valley. She previously covered real estate for the Los Angeles Business Journal. She has done work with publications including The Orange County Register, The Real Deal and doityourself.com.

Featured Articles

Related Articles